Safety Study of Nebivolol for COPD Patients

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
High Blood Pressure
Interventions
DRUG

Placebo

The placebo looks like the study drug but it does not contain active ingredients.

DRUG

Nebivolol

5 to 10mg per day

Trial Locations (1)

60637

University of Chicago Medical Center, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

University of Chicago

OTHER

NCT01939990 - Safety Study of Nebivolol for COPD Patients | Biotech Hunter | Biotech Hunter